Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
G04CB02
|
| gptkbp:brand |
gptkb:dutasteride
|
| gptkbp:CASNumber |
164656-23-9
|
| gptkbp:chemicalFormula |
C27H30F6N2O2
|
| gptkbp:contraindication |
children
pregnancy |
| gptkbp:drugClass |
5-alpha-reductase inhibitor
|
| gptkbp:eliminationHalfLife |
5 weeks
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avodart
|
| gptkbp:indication |
enlarged prostate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
5-alpha-reductase inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:notRecommendedFor |
gptkb:women
children |
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:riskFactor |
may increase risk of high-grade prostate cancer
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
decreased libido
gynecomastia ejaculation disorders impotence |
| gptkbp:usedFor |
gptkb:benign_prostatic_hyperplasia
|
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:bfsLayer |
6
|